STOCK TITAN
  1. Home
  2. News
  3. GENE

Genetic Technologies - GENE STOCK NEWS

Welcome to our dedicated page for Genetic Technologies news (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies stock.

Genetic Technologies Limited (GENE) delivers innovative genomic risk assessment solutions through its geneType and EasyDNA platforms. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in predictive diagnostics, strategic collaborations, and regulatory milestones.

Access official press releases covering quarterly earnings, product validations, patent approvals, and partnership announcements. Our curated feed simplifies tracking of GENE’s progress in integrating genetic insights into clinical decision-making and consumer health programs.

Discover updates about the company’s molecular testing innovations, including developments in oncology risk stratification and population health initiatives. Content spans financial disclosures, research breakthroughs, and global expansion efforts across healthcare markets.

Bookmark this page for streamlined access to verified information about Genetic Technologies’ operational developments. Check regularly for new insights into how GENE continues shaping personalized medicine through advanced DNA analysis technologies.

News

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Genetic Technologies is focusing on commercializing its geneType multi-risk test, while BioVie is developing therapies for neurodegeneration and liver disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
none
-
News

GTG to pilot GeneType in Breast Screen centers across the U.S.

Rhea-AI Summary
Genetic Technologies (NASDAQ: GENE) announces a clinical implementation study with breast imaging centers in New York, Miami, and Houston. The study aims to streamline care by integrating geneType into imaging centers, benefiting women at increased risk of breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
none
-
News

EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”

Rhea-AI Summary
Genetic Technologies (NASDAQ: GENE) partners with Humanise Health to launch 'Know Your Risk' event for women's health empowerment, featuring Risk Assessment portfolio at The Langham, Pasadena, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
News

Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market

Rhea-AI Summary
Genetic Technologies (GENE) announces a successful digital strategy led by Dr. Malcolm Bohm, resulting in significant increases in social media metrics. Consumer reach is up 56.3%, content interactions up 503%, and engagement up 175%. The company predicts a surge in adoption of risk assessment tests, shifting focus from 'sickcare' to 'healthcare'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none
-
News

GTG Global Collaborations and Innovation Update

Rhea-AI Summary
Genetic Technologies (GENE) announces its commitment to innovation through strong global academic partnerships, continuous enhancement of geneType portfolio, and expansion of risk assessment tests. Collaborations with high-profile universities, ongoing research projects, and development of new tests demonstrate GTG's dedication to improving patient care and personalized medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
none
-
News

GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Rhea-AI Summary
Genetic Technologies (GENE) announces the development of a groundbreaking risk assessment test for serious diseases, incorporating over 200 high penetrant genes to identify nearly 100% of people at risk. The test covers common cancers, cardiovascular disease, and type 2 diabetes, going beyond family history to identify patients at risk of disease. This innovation aims to revolutionize personalized preventative healthcare, providing physicians and patients with unparalleled insight into individual risk profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
none
News

GTG to launch U.S. Customer Digital Media Sales Campaign

Rhea-AI Summary
Genetic Technologies Limited (NASDAQ: GENE) announces the launch of a digital advertising campaign in the U.S. to drive Consumer Initiated Testing for geneType Risk Assessment Tests. The U.S. wellness testing market is projected to grow significantly, presenting a lucrative opportunity for GTG to tap into. Dr. Malcolm Bohm, a seasoned strategic advisor, will lead the initiative, leveraging his expertise in customer marketing and disruptive technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
News

Launching our most comprehensive test and expanding into new global markets

Rhea-AI Summary
Genetic Technologies Limited (NASDAQ: GENE) has released a business update for the quarter ending 31 December 2023, showcasing its pioneering initiatives in genomics-based tests for precision medicine. The company reported cash receipts totaling A$3.6m, including A$1.85m from customers and A$1.75 million from R&D Tax Incentive. Genetic Technologies also announced the appointment of 2 experienced commercial advisors to accelerate its Direct to Consumer plans for Genetype in the U.S. The company processed a record number of geneType tests and launched the Hereditary Breast & Ovarian Cancer Risk Assessment Test (HBOC) in the U.S. It also commenced a Precision Medicine Pilot with the Gold Coast Private Hospital and is expanding its global footprint in South East Asia and the UK. Genetic Technologies has also initiated activities associated with the CASSOWARY Trial, named as the sole industry partner for the $2.4 million clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
News

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary
Genetic Technologies Limited (NASDAQ: GENE) has regained compliance with the minimum bid price requirement set forth by Nasdaq, maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, as announced on January 05, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
News

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering various diseases, with a global market expected to reach $4.6 billion by 2025. BioVie is a clinical-stage company developing transformative therapies for Alzheimer's, Parkinson's, and liver diseases, with positive trending data from a Phase 3 trial in AD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
Stock GENE logo
Genetic Technologies

Nasdaq:GENE

GENE Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

GENE Stock Data

3.71M
4.85M
1.87%
0.53%
Diagnostics & Research
Healthcare
Link
Australia
Prahran